Mean daily use of oral corticosteroids per person per day · people with asthma
1 finding from 1 review
Cost of treatment per person at 1 year · people with asthma
1 finding from 1 review
Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy · adult parapneumonic effusions and empyema
Alteplase showed no clear difference in overall treatment failure, including mortality, thoracic surgery or… compared with urokinase (low certainty).
1 finding from 1 review
Overall treatment failure, including mortality, thoracic surgery or referral for further fibrinolytic therapy · adult parapneumonic effusions and empyema
Streptokinase showed no clear difference in overall treatment failure, including mortality, thoracic surgery or… compared with urokinase (low certainty).
1 finding from 1 review
Exacerbations · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
1 finding from 1 review
Response rate ‐ treatment failure · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
Fluoroquinolones may leads to lower response rate ‐ treatment failure compared with amoxicillin (low certainty).
1 finding from 1 review
Response rate ‐ microbiological response · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
Fluoroquinolones may leads to higher response rate ‐ microbiological response compared with amoxicillin (low certainty).
1 finding from 1 review
Response rate ‐ improvement in sputum purulence (excellent) · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
It is very uncertain whether fluoroquinolones changes response rate ‐ improvement in sputum purulence (excellent) compared with amoxicillin (very low certainty).
1 finding from 1 review
Deaths · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
1 finding from 1 review
Quality of life · adults aged 18 years and above with diagnosis of non‐cystic fibrosis bronchiectasis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Change from baseline in blood eosinophils (cells x 10*9/L) · children and adults with asthma
1 finding from 1 review
Minor adverse events · erectile dysfunction in men with obstructive sleep apnoea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Minor adverse events · erectile dysfunction in men with obstructive sleep apnoea
It is very uncertain whether continuous positive airway pressure (CPAP) changes minor adverse events compared with phosphodiesterase type 5 inhibitors (very low certainty).
1 finding from 1 review
Minor adverse events · erectile dysfunction in men with obstructive sleep apnoea
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Rate of moderate or severe exacerbations Eosinophilic phenotype · patients with chronic obstructive pulmonary disease
Mepolizumab 100 mg leads to lower rate of moderate or severe exacerbations Eosinophilic phenotype compared with placebo (high certainty).
1 finding from 1 review
Rate of moderate or severe exacerbations Eosinophilic phenotype · patients with chronic obstructive pulmonary disease
Mepolizumab 300 mg showed no clear difference in rate of moderate or severe exacerbations Eosinophilic phenotype compared with placebo (moderate certainty).
1 finding from 1 review
Time to first moderate or severe exacerbation Eosinophilic phenotype · patients with chronic obstructive pulmonary disease
Mepolizumab 300 mg probably leads to lower time to first moderate or severe exacerbation Eosinophilic phenotype compared with placebo (moderate certainty).
1 finding from 1 review
Rate of exacerbations with ED visit or hospitalisations Eosinophilic phenotype · patients with chronic obstructive pulmonary disease
Mepolizumab 300 mg showed no clear difference in rate of exacerbations with ED visit or hospitalisations Eosinophilic… compared with placebo (moderate certainty).
1 finding from 1 review
QoL · patients with chronic obstructive pulmonary disease
1 finding from 1 review